The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis

Background We examined whether determinants of disease progression and causes of death differ between injecting drug users (IDUs) and non‐IDUs who initiate combination antiretroviral therapy (cART). Methods The ART Cohort Collaboration combines data from participating cohort studies on cART‐naïve ad...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:HIV medicine 2012-02, Vol.13 (2), p.89-97
Hauptverfasser: Murray, M, Hogg, RS, Lima, VD, May, MT, Moore, DM, Abgrall, S, Bruyand, M, D'Arminio Monforte, A, Tural, C, Gill, MJ, Harris, RJ, Reiss, P, Justice, A, Kirk, O, Saag, M, Smith, CJ, Weber, R, Rockstroh, J, Khaykin, P, Sterne, JAC
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 97
container_issue 2
container_start_page 89
container_title HIV medicine
container_volume 13
creator Murray, M
Hogg, RS
Lima, VD
May, MT
Moore, DM
Abgrall, S
Bruyand, M
D'Arminio Monforte, A
Tural, C
Gill, MJ
Harris, RJ
Reiss, P
Justice, A
Kirk, O
Saag, M
Smith, CJ
Weber, R
Rockstroh, J
Khaykin, P
Sterne, JAC
description Background We examined whether determinants of disease progression and causes of death differ between injecting drug users (IDUs) and non‐IDUs who initiate combination antiretroviral therapy (cART). Methods The ART Cohort Collaboration combines data from participating cohort studies on cART‐naïve adults from cART initiation. We used Cox models to estimate hazard ratios for death and AIDS among IDUs and non‐IDUs. The cumulative incidence of specific causes of death was calculated and compared using methods that allow for competing risks. Results Data on 6269 IDUs and 37 774 non‐IDUs were analysed. Compared with non‐IDUs, a lower proportion of IDUs initiated cART with a CD4 cell count
doi_str_mv 10.1111/j.1468-1293.2011.00940.x
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4539012</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>920800532</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5700-79f2b654cefe9feacf5e5fe1ff949af3a07fe66942fa982220507bd36d46fd643</originalsourceid><addsrcrecordid>eNqNkc1u1TAQhSMEoqXwCsg7Vgm282uEkFAFtFIlNoWt5STjG18lcbCd22bHI_A2vA9PwiS3XMEOb3w0PvN57BNFhNGE4Xq9T1hWVDHjIk04ZSyhVGQ0uX8UnZ8OHm86i3lR8LPomfd7SlmZCvo0OuOsYiLn4jz6edsBAa2hCcRqYsY9KjPuSOvmHZk9kM74YN1C7Eha40FhaXJ258B7gzU1tqQFFTqiBot9V9dff33_MVlvgjkAAltzMO2seo8aa2qjN3aozYh6IwTjIDh7ME71JHTg1LS8QU_fq9o6tYEa21kX0Kz6xRv_PHqikQkvHvaL6MvHD7eXV_HN50_Xl-9v4iYvKY1LoXld5FkDGoQG1egccg1Ma5EJpVNFSw1FITKulag45zSnZd2mRZsVui2y9CJ6d-ROcz1A28AYcEg5OTMot0irjPz3ZDSd3NmDzHL8asYR8OoB4Oy3GXyQg_EN4NNGsLOXgtOK0jxdndXR2TjrvQN9uoVRucYu93JNV67pyjV2ucUu77H15d9Tnhr_5IyGt0fDnelh-W-wxDRRpL8BeEvEhw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>920800532</pqid></control><display><type>article</type><title>The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis</title><source>Wiley Free Content</source><source>MEDLINE</source><source>IngentaConnect Free/Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Murray, M ; Hogg, RS ; Lima, VD ; May, MT ; Moore, DM ; Abgrall, S ; Bruyand, M ; D'Arminio Monforte, A ; Tural, C ; Gill, MJ ; Harris, RJ ; Reiss, P ; Justice, A ; Kirk, O ; Saag, M ; Smith, CJ ; Weber, R ; Rockstroh, J ; Khaykin, P ; Sterne, JAC</creator><creatorcontrib>Murray, M ; Hogg, RS ; Lima, VD ; May, MT ; Moore, DM ; Abgrall, S ; Bruyand, M ; D'Arminio Monforte, A ; Tural, C ; Gill, MJ ; Harris, RJ ; Reiss, P ; Justice, A ; Kirk, O ; Saag, M ; Smith, CJ ; Weber, R ; Rockstroh, J ; Khaykin, P ; Sterne, JAC ; Antiretroviral Therapy Cohort Collaboration (ART-CC) ; for the Antiretroviral Therapy Cohort Collaboration (ART‐CC)</creatorcontrib><description>Background We examined whether determinants of disease progression and causes of death differ between injecting drug users (IDUs) and non‐IDUs who initiate combination antiretroviral therapy (cART). Methods The ART Cohort Collaboration combines data from participating cohort studies on cART‐naïve adults from cART initiation. We used Cox models to estimate hazard ratios for death and AIDS among IDUs and non‐IDUs. The cumulative incidence of specific causes of death was calculated and compared using methods that allow for competing risks. Results Data on 6269 IDUs and 37 774 non‐IDUs were analysed. Compared with non‐IDUs, a lower proportion of IDUs initiated cART with a CD4 cell count &lt;200 cells/μL or had a prior diagnosis of AIDS. Mortality rates were higher in IDUs than in non‐IDUs (2.08 vs. 1.04 per 100 person‐years, respectively; P&lt;0.001). Lower baseline CD4 cell count, higher baseline HIV viral load, clinical AIDS at baseline, and later year of cART initiation were associated with disease progression in both groups. However, the inverse association of baseline CD4 cell count with AIDS and death appeared stronger in non‐IDUs than in IDUs. The risk of death from each specific cause was higher in IDUs than non‐IDUs, with particularly marked increases in risk for liver‐related deaths, and those from violence and non‐AIDS infection. Conclusion While liver‐related deaths and deaths from direct effects of substance abuse appear to explain much of the excess mortality in IDUs, they are at increased risk for many other causes of death, which may relate to suboptimal management of HIV disease in these individuals.</description><identifier>ISSN: 1464-2662</identifier><identifier>EISSN: 1468-1293</identifier><identifier>DOI: 10.1111/j.1468-1293.2011.00940.x</identifier><identifier>PMID: 21819529</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Acquired immune deficiency syndrome ; Adolescent ; Adult ; Aggression ; AIDS-Related Opportunistic Infections - mortality ; Anti-HIV Agents - therapeutic use ; antiretroviral therapy ; CD4 antigen ; CD4 Lymphocyte Count ; Cohort Studies ; Data processing ; death ; Disease Progression ; Drug abuse ; Drug Therapy, Combination ; Drug Users - statistics &amp; numerical data ; Female ; hepatitis ; HIV Infections - drug therapy ; HIV Infections - etiology ; HIV Infections - immunology ; HIV Infections - mortality ; Human immunodeficiency virus ; Humans ; Infection ; injecting drug use ; Male ; Middle Aged ; Mortality ; Odds Ratio ; prognosis ; Proportional Hazards Models ; Risk Factors ; RNA, Viral - blood ; Substance Abuse, Intravenous - complications ; Substance Abuse, Intravenous - mortality ; Viral Load ; Young Adult</subject><ispartof>HIV medicine, 2012-02, Vol.13 (2), p.89-97</ispartof><rights>2011 British HIV Association</rights><rights>2011 British HIV Association.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5700-79f2b654cefe9feacf5e5fe1ff949af3a07fe66942fa982220507bd36d46fd643</citedby><cites>FETCH-LOGICAL-c5700-79f2b654cefe9feacf5e5fe1ff949af3a07fe66942fa982220507bd36d46fd643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1468-1293.2011.00940.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1468-1293.2011.00940.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21819529$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Murray, M</creatorcontrib><creatorcontrib>Hogg, RS</creatorcontrib><creatorcontrib>Lima, VD</creatorcontrib><creatorcontrib>May, MT</creatorcontrib><creatorcontrib>Moore, DM</creatorcontrib><creatorcontrib>Abgrall, S</creatorcontrib><creatorcontrib>Bruyand, M</creatorcontrib><creatorcontrib>D'Arminio Monforte, A</creatorcontrib><creatorcontrib>Tural, C</creatorcontrib><creatorcontrib>Gill, MJ</creatorcontrib><creatorcontrib>Harris, RJ</creatorcontrib><creatorcontrib>Reiss, P</creatorcontrib><creatorcontrib>Justice, A</creatorcontrib><creatorcontrib>Kirk, O</creatorcontrib><creatorcontrib>Saag, M</creatorcontrib><creatorcontrib>Smith, CJ</creatorcontrib><creatorcontrib>Weber, R</creatorcontrib><creatorcontrib>Rockstroh, J</creatorcontrib><creatorcontrib>Khaykin, P</creatorcontrib><creatorcontrib>Sterne, JAC</creatorcontrib><creatorcontrib>Antiretroviral Therapy Cohort Collaboration (ART-CC)</creatorcontrib><creatorcontrib>for the Antiretroviral Therapy Cohort Collaboration (ART‐CC)</creatorcontrib><title>The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis</title><title>HIV medicine</title><addtitle>HIV Med</addtitle><description>Background We examined whether determinants of disease progression and causes of death differ between injecting drug users (IDUs) and non‐IDUs who initiate combination antiretroviral therapy (cART). Methods The ART Cohort Collaboration combines data from participating cohort studies on cART‐naïve adults from cART initiation. We used Cox models to estimate hazard ratios for death and AIDS among IDUs and non‐IDUs. The cumulative incidence of specific causes of death was calculated and compared using methods that allow for competing risks. Results Data on 6269 IDUs and 37 774 non‐IDUs were analysed. Compared with non‐IDUs, a lower proportion of IDUs initiated cART with a CD4 cell count &lt;200 cells/μL or had a prior diagnosis of AIDS. Mortality rates were higher in IDUs than in non‐IDUs (2.08 vs. 1.04 per 100 person‐years, respectively; P&lt;0.001). Lower baseline CD4 cell count, higher baseline HIV viral load, clinical AIDS at baseline, and later year of cART initiation were associated with disease progression in both groups. However, the inverse association of baseline CD4 cell count with AIDS and death appeared stronger in non‐IDUs than in IDUs. The risk of death from each specific cause was higher in IDUs than non‐IDUs, with particularly marked increases in risk for liver‐related deaths, and those from violence and non‐AIDS infection. Conclusion While liver‐related deaths and deaths from direct effects of substance abuse appear to explain much of the excess mortality in IDUs, they are at increased risk for many other causes of death, which may relate to suboptimal management of HIV disease in these individuals.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aggression</subject><subject>AIDS-Related Opportunistic Infections - mortality</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>antiretroviral therapy</subject><subject>CD4 antigen</subject><subject>CD4 Lymphocyte Count</subject><subject>Cohort Studies</subject><subject>Data processing</subject><subject>death</subject><subject>Disease Progression</subject><subject>Drug abuse</subject><subject>Drug Therapy, Combination</subject><subject>Drug Users - statistics &amp; numerical data</subject><subject>Female</subject><subject>hepatitis</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - etiology</subject><subject>HIV Infections - immunology</subject><subject>HIV Infections - mortality</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infection</subject><subject>injecting drug use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Odds Ratio</subject><subject>prognosis</subject><subject>Proportional Hazards Models</subject><subject>Risk Factors</subject><subject>RNA, Viral - blood</subject><subject>Substance Abuse, Intravenous - complications</subject><subject>Substance Abuse, Intravenous - mortality</subject><subject>Viral Load</subject><subject>Young Adult</subject><issn>1464-2662</issn><issn>1468-1293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1u1TAQhSMEoqXwCsg7Vgm282uEkFAFtFIlNoWt5STjG18lcbCd22bHI_A2vA9PwiS3XMEOb3w0PvN57BNFhNGE4Xq9T1hWVDHjIk04ZSyhVGQ0uX8UnZ8OHm86i3lR8LPomfd7SlmZCvo0OuOsYiLn4jz6edsBAa2hCcRqYsY9KjPuSOvmHZk9kM74YN1C7Eha40FhaXJ258B7gzU1tqQFFTqiBot9V9dff33_MVlvgjkAAltzMO2seo8aa2qjN3aozYh6IwTjIDh7ME71JHTg1LS8QU_fq9o6tYEa21kX0Kz6xRv_PHqikQkvHvaL6MvHD7eXV_HN50_Xl-9v4iYvKY1LoXld5FkDGoQG1egccg1Ma5EJpVNFSw1FITKulag45zSnZd2mRZsVui2y9CJ6d-ROcz1A28AYcEg5OTMot0irjPz3ZDSd3NmDzHL8asYR8OoB4Oy3GXyQg_EN4NNGsLOXgtOK0jxdndXR2TjrvQN9uoVRucYu93JNV67pyjV2ucUu77H15d9Tnhr_5IyGt0fDnelh-W-wxDRRpL8BeEvEhw</recordid><startdate>201202</startdate><enddate>201202</enddate><creator>Murray, M</creator><creator>Hogg, RS</creator><creator>Lima, VD</creator><creator>May, MT</creator><creator>Moore, DM</creator><creator>Abgrall, S</creator><creator>Bruyand, M</creator><creator>D'Arminio Monforte, A</creator><creator>Tural, C</creator><creator>Gill, MJ</creator><creator>Harris, RJ</creator><creator>Reiss, P</creator><creator>Justice, A</creator><creator>Kirk, O</creator><creator>Saag, M</creator><creator>Smith, CJ</creator><creator>Weber, R</creator><creator>Rockstroh, J</creator><creator>Khaykin, P</creator><creator>Sterne, JAC</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>201202</creationdate><title>The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis</title><author>Murray, M ; Hogg, RS ; Lima, VD ; May, MT ; Moore, DM ; Abgrall, S ; Bruyand, M ; D'Arminio Monforte, A ; Tural, C ; Gill, MJ ; Harris, RJ ; Reiss, P ; Justice, A ; Kirk, O ; Saag, M ; Smith, CJ ; Weber, R ; Rockstroh, J ; Khaykin, P ; Sterne, JAC</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5700-79f2b654cefe9feacf5e5fe1ff949af3a07fe66942fa982220507bd36d46fd643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aggression</topic><topic>AIDS-Related Opportunistic Infections - mortality</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>antiretroviral therapy</topic><topic>CD4 antigen</topic><topic>CD4 Lymphocyte Count</topic><topic>Cohort Studies</topic><topic>Data processing</topic><topic>death</topic><topic>Disease Progression</topic><topic>Drug abuse</topic><topic>Drug Therapy, Combination</topic><topic>Drug Users - statistics &amp; numerical data</topic><topic>Female</topic><topic>hepatitis</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - etiology</topic><topic>HIV Infections - immunology</topic><topic>HIV Infections - mortality</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infection</topic><topic>injecting drug use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Odds Ratio</topic><topic>prognosis</topic><topic>Proportional Hazards Models</topic><topic>Risk Factors</topic><topic>RNA, Viral - blood</topic><topic>Substance Abuse, Intravenous - complications</topic><topic>Substance Abuse, Intravenous - mortality</topic><topic>Viral Load</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murray, M</creatorcontrib><creatorcontrib>Hogg, RS</creatorcontrib><creatorcontrib>Lima, VD</creatorcontrib><creatorcontrib>May, MT</creatorcontrib><creatorcontrib>Moore, DM</creatorcontrib><creatorcontrib>Abgrall, S</creatorcontrib><creatorcontrib>Bruyand, M</creatorcontrib><creatorcontrib>D'Arminio Monforte, A</creatorcontrib><creatorcontrib>Tural, C</creatorcontrib><creatorcontrib>Gill, MJ</creatorcontrib><creatorcontrib>Harris, RJ</creatorcontrib><creatorcontrib>Reiss, P</creatorcontrib><creatorcontrib>Justice, A</creatorcontrib><creatorcontrib>Kirk, O</creatorcontrib><creatorcontrib>Saag, M</creatorcontrib><creatorcontrib>Smith, CJ</creatorcontrib><creatorcontrib>Weber, R</creatorcontrib><creatorcontrib>Rockstroh, J</creatorcontrib><creatorcontrib>Khaykin, P</creatorcontrib><creatorcontrib>Sterne, JAC</creatorcontrib><creatorcontrib>Antiretroviral Therapy Cohort Collaboration (ART-CC)</creatorcontrib><creatorcontrib>for the Antiretroviral Therapy Cohort Collaboration (ART‐CC)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>HIV medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murray, M</au><au>Hogg, RS</au><au>Lima, VD</au><au>May, MT</au><au>Moore, DM</au><au>Abgrall, S</au><au>Bruyand, M</au><au>D'Arminio Monforte, A</au><au>Tural, C</au><au>Gill, MJ</au><au>Harris, RJ</au><au>Reiss, P</au><au>Justice, A</au><au>Kirk, O</au><au>Saag, M</au><au>Smith, CJ</au><au>Weber, R</au><au>Rockstroh, J</au><au>Khaykin, P</au><au>Sterne, JAC</au><aucorp>Antiretroviral Therapy Cohort Collaboration (ART-CC)</aucorp><aucorp>for the Antiretroviral Therapy Cohort Collaboration (ART‐CC)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis</atitle><jtitle>HIV medicine</jtitle><addtitle>HIV Med</addtitle><date>2012-02</date><risdate>2012</risdate><volume>13</volume><issue>2</issue><spage>89</spage><epage>97</epage><pages>89-97</pages><issn>1464-2662</issn><eissn>1468-1293</eissn><abstract>Background We examined whether determinants of disease progression and causes of death differ between injecting drug users (IDUs) and non‐IDUs who initiate combination antiretroviral therapy (cART). Methods The ART Cohort Collaboration combines data from participating cohort studies on cART‐naïve adults from cART initiation. We used Cox models to estimate hazard ratios for death and AIDS among IDUs and non‐IDUs. The cumulative incidence of specific causes of death was calculated and compared using methods that allow for competing risks. Results Data on 6269 IDUs and 37 774 non‐IDUs were analysed. Compared with non‐IDUs, a lower proportion of IDUs initiated cART with a CD4 cell count &lt;200 cells/μL or had a prior diagnosis of AIDS. Mortality rates were higher in IDUs than in non‐IDUs (2.08 vs. 1.04 per 100 person‐years, respectively; P&lt;0.001). Lower baseline CD4 cell count, higher baseline HIV viral load, clinical AIDS at baseline, and later year of cART initiation were associated with disease progression in both groups. However, the inverse association of baseline CD4 cell count with AIDS and death appeared stronger in non‐IDUs than in IDUs. The risk of death from each specific cause was higher in IDUs than non‐IDUs, with particularly marked increases in risk for liver‐related deaths, and those from violence and non‐AIDS infection. Conclusion While liver‐related deaths and deaths from direct effects of substance abuse appear to explain much of the excess mortality in IDUs, they are at increased risk for many other causes of death, which may relate to suboptimal management of HIV disease in these individuals.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21819529</pmid><doi>10.1111/j.1468-1293.2011.00940.x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1464-2662
ispartof HIV medicine, 2012-02, Vol.13 (2), p.89-97
issn 1464-2662
1468-1293
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4539012
source Wiley Free Content; MEDLINE; IngentaConnect Free/Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Acquired immune deficiency syndrome
Adolescent
Adult
Aggression
AIDS-Related Opportunistic Infections - mortality
Anti-HIV Agents - therapeutic use
antiretroviral therapy
CD4 antigen
CD4 Lymphocyte Count
Cohort Studies
Data processing
death
Disease Progression
Drug abuse
Drug Therapy, Combination
Drug Users - statistics & numerical data
Female
hepatitis
HIV Infections - drug therapy
HIV Infections - etiology
HIV Infections - immunology
HIV Infections - mortality
Human immunodeficiency virus
Humans
Infection
injecting drug use
Male
Middle Aged
Mortality
Odds Ratio
prognosis
Proportional Hazards Models
Risk Factors
RNA, Viral - blood
Substance Abuse, Intravenous - complications
Substance Abuse, Intravenous - mortality
Viral Load
Young Adult
title The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T15%3A46%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20injecting%20drug%20use%20history%20on%20disease%20progression%20and%20death%20among%20HIV%E2%80%90positive%20individuals%20initiating%20combination%20antiretroviral%20therapy:%20collaborative%20cohort%20analysis&rft.jtitle=HIV%20medicine&rft.au=Murray,%20M&rft.aucorp=Antiretroviral%20Therapy%20Cohort%20Collaboration%20(ART-CC)&rft.date=2012-02&rft.volume=13&rft.issue=2&rft.spage=89&rft.epage=97&rft.pages=89-97&rft.issn=1464-2662&rft.eissn=1468-1293&rft_id=info:doi/10.1111/j.1468-1293.2011.00940.x&rft_dat=%3Cproquest_pubme%3E920800532%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=920800532&rft_id=info:pmid/21819529&rfr_iscdi=true